Taipei, Taiwan – Asia-Pacific specialist CRO Novotech announced today that leading National Taiwan University Hospital (NTUH), has joined the Novotech Partnership Program.
The Partnership was signed at an official ceremony in Taipei.
The award-winning Asia-Pacific CRO, has 23 years of experience in the region and access to more than 1.4 billion people living in urban areas. The NTUH partnership has further strengthened its presence in the Asia-Pacific.
Novotech now has 25 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to bring unparalleled access to quality investigators, KOLs, and patients for its international biotech clients.
NTUH is internationally recognized for its leadership role in biotechnology industry R&D and clinical implementation.
The Hospital is at the forefront of clinical research having established the "National Center of Excellence for Clinical Trial and Research" in 2005 in response to the Government’s "Biotech Takeoff Diamond Action Plan" initiative.
NTUH conducts hundreds of clinical trials each year including drugs, medical device, vaccine, cell therapy, and procedures for a wide range of disease conditions.
In addition, many NTUH researchers are principal investigators and members of steering committee for these international clinical trials.
Novotech Executive Director Asia Operations Dr. Yooni Kim said the Partnership with NTUH is designed to support the increased demand for clinical trials from both Western and Asian biotechs.
Novotech has on the ground clinical team leader with deep local expertise to deliver CRO services for biotechnology companies across Taiwan. Novotech has about 30 employees working locally with biotechnology clients across Taiwan. Novotech applies its scientific expertise to reducing clinical trial timelines to assist biotechnology companies with their clinical research in Taiwan. Biotechnology clinical trials are becoming increasingly complex and target smaller patient populations. This requires a deep understanding of each location specificities and nurturing relationships with key investigators. The Taiwanese Ministry for Health and Welfare Food and Drug Administration (TFDA) has considerably simplified its First In Human (FIH) regulatory approval process over the past years, prompting biotechnology sponsors to consider this location for their clinical trials.
“Our biotech clients want seamless regional clinical research sites with the best investigators and research teams so we are pleased to have NTUH in the Novotech Partnership Program.”
Taiwan has become a key destination for biotechnology trials because of the large population concentrated in a few cities, which simplifies the patient recruitment process, and streamlined regulatory process. Moreover, Taiwanese enjoy high National Health coverage.
Novotech has on the ground clinical team leader with deep local expertise to deliver CRO services for biotechnology companies across Taiwan.
Novotech has about 30 employees working locally with biotechnology clients across Taiwan.
Novotech applies its scientific expertise to reducing clinical trial timelines to assist biotechnology companies with their clinical research in Taiwan.
Biotechnology clinical trials are becoming increasingly complex and target smaller patient populations. This requires a deep understanding of each location specificities and nurturing relationships with key investigators.
The Taiwanese Ministry for Health and Welfare Food and Drug Administration (TFDA) has considerably simplified its First In Human (FIH) regulatory approval process over the past years, prompting biotechnology sponsors to consider this location for their clinical trials.
